Introduction
Alefacept (Amevive) is a novel dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 linked to the Fc portion of human IgG1 that selectively targets the memory T-cell population. It is successfully used in psoriasis 1, 2 and is being used (off label) in a variety of other disorders. 3 In addition, in psoriatic patients, it was already reported that alefacept causes a selective reduction in circulating effector memory T cells 4 and that there is a reduction in the total number of conventional memory T and natural killer (NK)-T cells, whereas no statistically significant changes were seen in NK cells and CD4 þ 25 þ . 5 Chronic GVHD (cGVHD) is a common complication after allo-SCT occurring in 30-50% of transplant survivors. It is the leading cause of nonrelapse mortality in transplant survivors and has a significant impact on their functional status and quality of life. 6 Our group 7 and others 8 have shown that alefacept is active in steroidresistant or steroid-dependent acute GVHD (aGVHD). Considering the relatively low rate of the side effects of alefacept, its efficacy in psoriasis and GVHD, and its effect on T-cell subtypes, we decided to investigate the role of alefacept in a cohort of patients with refractory extensive cGVHD and its possible cellular immunomodulation.
Patients and methods

Patient's characteristics and GVHD policy
Twelve patients were included in the preliminary study, seven males and five females with a median age of 27 years (range 3-60). The disease for which the transplantation was done was AML (n ¼ 5), ALL (n ¼ 3), non-Hodgkin's lymphoma (n ¼ 1), melanoma (n ¼ 1), pure red cell aplasia (n ¼ 1) and hemophagocytosis (n ¼ 1). Seven patients were transplanted from HLA-A, B, C and high-resolution DR fully matched family donors; two patients received stem cell graft from fully matched unrelated donor nonreactive in mixed lymphocyte culture; two patients were transplanted from partially matched siblings and one from a 6/6 matched unrelated cord blood unit. Patient characteristics are shown in Table 1 . Initially, treatment of each patient was individually authorized by the institutional review board as an off-label use of the drug and later on the study was approved by the institutional review board (PRS number NCT003973320).
Patients were eligible for inclusion if they developed extensive cGVHD that was resistant to at least two lines of therapy, which in all patients included prednisone (X1 mg/ kg), and the minimum duration of pre-inclusion therapy was 3 months. New immune-suppressive medications were not added during the study. GVHD diagnosis was based on clinical criteria and in some patients supported by biopsy.
Alefacept treatment program
Alefacept (Amevive, Biogen Inc., Cambridge, MA, USA) was a gift from Medison Pharma Ltd, Israel.
On the basis of our experience in aGVHD, the dose needed was higher than the standard dose given to psoriatic patients. Therefore, the dose for children (up to 14 years of age) and adults was 15 and 30 mg, respectively, given intramuscularly once weekly.
Response criteria
Therapeutic response was defined as minimal, moderate or marked based on clinical (health-care provider global rating 9 ) and laboratory judgment. Response assessment was done during and after the termination of treatment.
All possible adverse reactions that could be attributed to alefacept were monitored, as well as infectious complications (including routine DNA-PCR test and/or pp65 antigenemia to detect CMV activation); the status of disease for which the transplantation was done and chimerism, including weekly donor and host-specific DNA markers, using male and female amelogenin gene PCR bands, 10 variable number of tandem repeats (VNTR)-PCR 11 and cytogenetic analysis where applicable.
Peripheral blood samples
Peripheral blood draws were taken during administration of alefacept. Neutrophil, lymphocyte and monocyte counts were determined by routine complete blood count. PBMCs were isolated from the heparinized samples using a standard Ficoll-Hypaque (Pharmacia Biotech Inc., Piscataway, NJ, USA) density gradient sedimentation.
PBMC phenotype
PBMCs were stained for 15 min at room temperature with the following antibodies (5 ml/10 5 cells): CD2, CD20, CD45RA (FITC), CD8, CD45RO, CD56 (phycoerythrin), CD3, CD4, CD8 (peridinin-chlorophyll-protein), CD3, CD45RO (allophycocyanin) (Becton Dickinson, NJ, USA). Cells were washed with FACSwash (0.1% sodium azide (Sigma Aldrich, Rehovot, Israel) and 2% FCS (Gibco-BRL Life Technologies, CA, USA) in PBS) and resuspended in 1.3% formaldehyde (Fisher Scientific, Waltham, MA, USA) in FACSwash. Samples were analyzed within 24 h with four-color staining using a FACSCalibur Flow Cytometer and CELLQuest software after calibration with CaliBRITE beads and FACSComp software (Becton Dickinson).
Results
Twelve patients were treated for 13 cGVHD episodes, and a median of 8 (range 1-25) alefacept injections (corresponding to 8 weeks of treatment) were given per patient (one patient had two episodes of cGVHD). Median time interval between SCT and cGVHD appearance was 100 days (range 100-1433) and median time interval from onset of GVHD to initiation of treatment was 13 months (median 3-37.6). Eight patients had cGVHD progressing from aGVHD, three had de novo cGVHD (two were associated with donor lymphocyte infusion (DLI)) and one had cGVHD appearing after the complete resolution of aGVHD (also associated with DLI). All patients suffered from extensive cGVHD and were unsuccessfully treated earlier with at least two immunosuppressive lines of therapy (median: 4, range: 2-13). System involvement included skin (n ¼ 11), mucocutaneous (n ¼ 9), liver (n ¼ 7), lungs (n ¼ 2), peripheral nervous system (n ¼ 1) and gastrointestinal tract (n ¼ 1) (Table 1) .
Response Nine of the 11 evaluable patients (one patient received only one injection because of the development of infection) showed response (10 of 12 evaluable episodes). The median time to initial response was 2.25 weeks and the response was marked (three episodes), moderate (two episodes) or minimal (four episodes). Responses were seen in the skin, mucosa (oral and vaginal) and lungs. One patient with pulmonary GVHD had a consistent pulmonary improvement ( Figure 1 ) while having only minimal cutaneous improvement, with an increase of 0.74 l (24%) in the functional vital capacity and 0.28 l of the forced expiratory volume at 1 s (FEV1) (18%), as measured by the end of alefacept treatment. The improvement in the pulmonary function continued, reaching a peak of an increase of 0.88 l (28%) in the functional vital capacity and 0.45 l of the FEV1 (27%). In two of the responding patients, the response was only temporary and progression appeared under alefacept treatment and therefore the treatment was stopped.
The response was durable in four of the surviving patients.
Adverse events
No immediate alefacept-related side effects were observed. None of the patients suffered from local complication at the site of injection. Later side effects included infections (n ¼ 3), pericarditis (n ¼ 1) and the appearance of squamous cell carcinoma of the lip (n ¼ 1). All these events may be related to the pronounced background immune suppression and other drugs given simultaneously.
Currently, 6 of 12 patients are alive, five with stable or improved cGVHD and one patient has progression of cGVHD. Six patients died because of cGVHD progression (one of whom received only one injection of alefacept), which was accompanied in most cases by infections. Full donor chimerism (100% donor cells and no residual hosttype DNA) was present in all patients and was stable throughout the treatment period. No relapse of the disease for which the patients were transplanted was observed in this group of patients until reporting (median follow-up 30 months, range 1-35).
Alefacept preferentially decreases circulating memory T-cell subsets
Informative data were acquired from five patients. A significant reduction of memory cells (CD45RO þ ), as compared with naive (CD45RA þ ) cells, was seen in all patients (Figure 2 ). In addition, we found in some patients a decrease in the percentage of the subtypes of T cells, including cytotoxic T cells or a decrease in the percentage of B cells.
Discussion
Chronic GVHD remains the major cause of late morbidity after allo-SCT and is the major cause of nonrelapse mortality and morbidity in long-term survivors.
12-14 In adults, the reported incidence of cGVHD ranges between 30 and 50% of HLA-identical sibling transplant recipients, with aGVHD being recognized as the most important factor predicting the development of the chronic form of the disease. [15] [16] [17] The increased use of matched unrelated volunteers as donors 18 and of peripheral blood as a stem cell source 19, 20 has led to a further increase of the incidence and severity of this complication.
One of the first immunological events in GVHD is the activation of donor T cells by encountering host-derived alloantigen-presenting cells. 21 In spite of all available modalities, not all of the patients achieve control of GVHD, which may rapidly lead to death. 22 Furthermore, the prognosis of steroid-resistant GVHD is usually poor. 23 In view of the failure of currently available anti-GVHD modalities, the clinical application of monoclonal antibodies and chimeric proteins normally used for the treatment of T-cell-dependent autoimmunity is currently increasing. 24, 25 As T cells are the backbone of GVHD activation, it is therefore logical that prevention and management of GVHD should focus on T-cell elimination or suppression of T-cell function or, preferably, on induction of specific transplantation tolerance. Alefacept (Amevive) is an immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 linked to the Fc (hinge, C H 2 and C H 3 domains) portion of human IgG1. It was shown to interfere with lymphocyte activation by specific binding to the lymphocyte antigen CD2 and inhibiting leukocyte function antigen-3/CD2 interaction.
Alefacept is the first therapeutic agent targeted to T lymphocytes that has been shown to have a selective effect on effector memory T cells vs central memory T cells in humans. As in GVHD, psoriasis is a T-cell-dependent immune disease of the skin and joints. Disease manifestation is orchestrated by proinflammatory CD4-positive T-helper cells producing either IFN-g (Th1) or IL-17 (Th17), which interact with dermal dendritic cells, macrophages, mast cells and neutrophils. 26 Differential effects of alefacept on naive vs central memory T cells and effector memory T cells T-cell pools relate to the increased CD2 expression on effector T cells and thus differential binding of alefacept to surface CD2 molecules. The relief in psoriasis is accompanied by the reduction of circulating populations that are differentiated as type 1 effectors (leukocyte function antigen-1hi, VLA-4hi, aEb7 þ , CLA þ and IFN-g-producing T cells), which argue for the roles of these T-cell subsets in disease pathogenesis. Indeed, these T-cell subsets are found to be concentrated in skin lesions of psoriasis. Alefacept was also shown to induce reduction in subsets of CD2 þ T lymphocytes (primarily CD45RO þ ), presumably by bridging between CD2 on target lymphocytes and Ig Fc receptors on cytotoxic cells, such as NK cells. 27 It was also shown that alefacept treatment results in a reduction in circulating total CD4 þ and CD8 þ T-lymphocyte counts.
We have shown earlier that in aGVHD, alefacept induces fast remission 7 even in patients with steroid refractoriness. In this study, we further explored the effect of alefacept in heavily pretreated patients (having history of a median of four earlier lines of treatment) with refractory extensive cGVHD. The protocol used was similar to the protocol used in psoriasis (that is, weekly i.m. injections) but with a double dose of alefacept.
The results of this study show that most patients (83%) showed a response. The response was pronounced in 42% (combination of marked and moderate response). In some patients, the response was good in some organs and minimal in others as judged clinically (and not by BSA rash or the NIH oral mucosal disease scores). For example, in one patient with pulmonary cGVHD (bronchiolitis obliterans), there was a gradual and consistent improvement of pulmonary function tests (Figure 1 ) while having only minimal dermatological response of scleroderma such as cGVHD. The improvement in his pulmonary cGVHD continued further after discontinuing alefacept. Thus, we show that alefacept has activity in the chronic phase of GVHD even in refractory extensive disease. The use of alefacept was well tolerated and accompanied by only minimal side effects that may be related to the cGVHD itself, general immunosuppression, immune dysregulation or other immunosuppressive agents used.
The clinical effect was accompanied by a decrease in the percentage of total lymphocytes, both B and T cells, in most patients. A significant reduction of memory cells (CD45RO þ ), as compared with naive (CD45RA þ ) cells was seen in all patients (Figure 2 ). In addition, we found in some patients a decrease in the percentage of the subtypes of T cells, including cytotoxic T cells, or a decrease in the percentage of B cells.
Thus, the mechanism of T-cell reductions remains to be established. The possible mechanisms of action include the bridging effect proposed earlier between T cells and NK cells leading to direct lymphocyte cell death. This may occur slowly, at least at the tissue level. Second, alefacept may preferentially bind to lesional T cells, resulting in a disruption of the organization of T cells and DCs in the tissue. 5, 28 Third, the binding of alefacept to lymphocyte CD2 may result in sequestration of the bound cell from circulation into lymphoid organs, and subsequent depletion. The fourth possibility is that there is a relative increase in tissue regulatory T cells.
Again, we hypothesize that the effect of alefacept on GVHD is augmented by the increased allogeneic NK-cell activity, 29 which in conjunction with the Fc end of the alefacept may induce cytotoxicity of alloreactive T cells, thus downregulating GVHD activity. We conclude that on the basis of our limited experience, alefacept is a promising agent for clinical application for treatment patients with extensive cGVHD even when refractory.
